Summary of Study ST000493

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000370. The data can be accessed directly via it's Project DOI: 10.21228/M87604 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST000493
Study TitleSleep apnea and cardiovascular samples SCFA, short chain fatty acids panel
Study SummarySleep apnea and cardiovascular samples SCFA, short chain fatty acids panel
Institute
Mayo Clinic
LaboratoryMayo Clinic Metabolomics Resource Core
Last NamePak
First NameVictoria
Addressunknown
Emailvictoria.pak@yale.edu
Phone203-737-5065
Submit Date2016-10-14
Analysis Type DetailGC-MS
Release Date2018-10-10
Release Version1
Victoria Pak Victoria Pak
https://dx.doi.org/10.21228/M87604
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000370
Project DOI:doi: 10.21228/M87604
Project Title:Mayo Metabolomics Pilot and Feasibility Award: Mechanisms of sleep apnea and cardiovascular disease
Project Type:MS targeted analysis
Project Summary:Targeted Metabolic and Biological Markers of Sleepiness Symptoms in Sleep apnea and cardiovascular disease
Institute:Mayo Clinic
Laboratory:Mayo Clinic Metabolomics Resource Core
Last Name:Pak
First Name:Victoria
Address:unknown
Email:victoria.pak@yale.edu
Phone:203-737-5065

Subject:

Subject ID:SU000514
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Disease
SA025572ms5688-12cardiovascular disease
SA025573ms5688-11cardiovascular disease
SA025574ms5688-14cardiovascular disease
SA025575ms5688-16cardiovascular disease
SA025576ms5688-1cardiovascular disease
SA025577ms5688-10cardiovascular disease
SA025578ms5688-15cardiovascular disease
SA025579ms5688-13cardiovascular disease
SA025580ms5688-3cardiovascular disease
SA025581ms5688-9cardiovascular disease
SA025582ms5688-2cardiovascular disease
SA025583ms5688-4cardiovascular disease
SA025584ms5688-5cardiovascular disease
SA025585ms5688-8cardiovascular disease
SA025586ms5688-7cardiovascular disease
SA025587ms5688-6cardiovascular disease
SA025588ms5688-31sleep apnea
SA025589ms5688-30sleep apnea
SA025590ms5688-29sleep apnea
SA025591ms5688-32sleep apnea
SA025592ms5688-36sleep apnea
SA025593ms5688-28sleep apnea
SA025594ms5688-35sleep apnea
SA025595ms5688-34sleep apnea
SA025596ms5688-33sleep apnea
SA025597ms5688-19sleep apnea
SA025598ms5688-21sleep apnea
SA025599ms5688-20sleep apnea
SA025600ms5688-18sleep apnea
SA025601ms5688-17sleep apnea
SA025602ms5688-22sleep apnea
SA025603ms5688-23sleep apnea
SA025604ms5688-26sleep apnea
SA025605ms5688-25sleep apnea
SA025606ms5688-24sleep apnea
SA025607ms5688-27sleep apnea
Showing results 1 to 36 of 36

Collection:

Collection ID:CO000508
Collection Summary:For the metabolic markers, 9 ml blood will be drawn into 3 EDTA tubes (3 ml each) and gently centrifuged at 4°C for 10 min; plasma aliquots were immediately frozen and stored at -80 °C; will be stored at -80ºC in the CTRC until all samples are collected and then sent to Mayo Clinic Metabolomics Core.
Sample Type:Blood

Treatment:

Treatment ID:TR000528
Treatment Summary:Recruitment of subjects will take place from the clinic population in collaboration with the Penn Sleep Center. Patients newly diagnosed with OSA will be solicited for via an overnight sleep study, which is general monitoring of sleep and variety of body functions during sleep. This includes brain (EEG), eye (EOG), and muscle activity and heart rhythm. The diagnosis of OSA will be established by full sleep study. First, the PI will screen for eligibility and obtain informed consent. We will assess height, weight, medical history, demographics. EDS will be measured subjectively on the night of enrollment in the study and determined using the Epworth Sleepiness Scale. The information regarding gender, BMI, smoking, age, medications (name/duration/frequency), and presence of comorbidities (e.g. hypertension, CVD defined by doctor diagnosis of myocardial infarction, stroke, or heart failure) will then be obtained via the electronic medical record. We will also ask subjects whether they exercise by asking participants the yes/no question: “During the past month, did you participate in any physical activities or exercises?” Second, the subject will undergo diagnostic PSG and we will enforce fasting prior to bedtime. Third, biological samples will be collected in the morning after the sleep study. Patients who have agreed to participate will undergo a blood draw (20 ml) and urine collection (30 ml) on the morning after PSG. Laboratory analysis of the biological samples will be conducted in collaboration with the Clinical Translation Research Center (CTRC). Finally, subjects will have 1 or 2 practice sessions with the PVT prior to administration of the task. PVT test will be conducted 3 times, at approximately 10:00, 12:00, and 14:00 and automatically scored. This will be done on the day after the sleep study.

Sample Preparation:

Sampleprep ID:SP000521
Sampleprep Summary:short chain fatty acids panel

Combined analysis:

Analysis ID AN000759
Analysis type MS
Chromatography type GC
Chromatography system Agilent 7890A
Column Agilent HP5-MS (30m × 0.25mm, 0.25 um)
MS Type EI
MS instrument type Single quadrupole
MS instrument name Agilent 5975C
Ion Mode POSITIVE
Units micromolar

Chromatography:

Chromatography ID:CH000545
Instrument Name:Agilent 7890A
Column Name:Agilent HP5-MS (30m × 0.25mm, 0.25 um)
Chromatography Type:GC

MS:

MS ID:MS000671
Analysis ID:AN000759
Instrument Name:Agilent 5975C
Instrument Type:Single quadrupole
MS Type:EI
Ion Mode:POSITIVE
  logo